Efficient Project Management for a Late-Stage Parkinson’s Disease Study 

1 minute read

Published: January 6th, 2026

Phastar partnered with a biotechnology sponsor to manage statistical and data management activities for a late-stage clinical study in Parkinson’s disease. The project involved distributed teams, complex neurosurgical procedures, and questionnaire-driven endpoints—all under tight budget oversight. 

Key Challenges: 

  • Global team coordination across multiple time zones 
  • Limited internal statistical and data management expertise 
  • Complex CRF design for neurosurgical injections and questionnaire-based endpoints 
  • Need for strict oversight and cost control 

Our Approach: 

  • Scheduled cross-time-zone meetings to maximize participation and maintain momentum 
  • Provided clear, proactive explanations to support sponsor understanding at each stage 
  • Conducted detailed multidisciplinary reviews of complex CRF pages 
  • Ensured strict adherence to the project timeline to minimize rework and control budget impact 

Outcome: 

The study progressed smoothly, earning strong praise from all stakeholders. The sponsor commended Phastar’s professionalism, attention to detail, and proactive approach, noting significant improvements in collaboration, clarity, and project efficiency. 

Complete the form below to read the full case study

Related articles

Translating Real-World Data into Commercial Success with Outcome Modelling 

Translating Real-World Data into Commercial Success with Outcome Modelling 

July 13th, 2026 1 minute read

Demonstrating real-world value is critical for securing pricing and market access, but bridging the gap between clini...

Scaling Real-World Evidence to Maximize Drug Lifecycle Value 

Scaling Real-World Evidence to Maximize Drug Lifecycle Value 

July 13th, 2026 1 minute read

Biopharma organizations have access to vast amounts of real-world data, but extracting meaningful, actionable insight...

Extending Trial Value with Long-Term Benefit–Risk Simulation in Prostate Cancer

Extending Trial Value with Long-Term Benefit–Risk Simulation in Prostate Cancer

July 13th, 2026 1 minute read

Demonstrating short-term efficacy is no longer enough, regulators increasingly require a clear understanding of long-...